欧盟 - 爱沙尼亚文 - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

欧盟 - 爱沙尼亚文 - EMA (European Medicines Agency)

intervet international bv - indoksakarb - nahaparasiidi paikseks kasutamiseks, sh. insektitsiidid, indoksakarbi - dogs; cats - kirpude nakatumise ravi ja ennetamine. koerte ja kasside puhul: kirpude nakatumise ravi ja vältimine. veterinaarravimit saab kasutada kirbuallergia dermatiidi ravistrateegia osana. pärast kokkupuudet activyl-ga töödeldud lemmikloomadega surmatakse tapaloomade vahetus läheduses asuvate kirbude staadiumid.

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

reckitt benckiser (poland) s.a. - flurbiprofeen - suuõõnesprei, lahus - 8,75mg 1annus 15ml 1tk

欧盟 - 爱沙尼亚文 - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - telmisartan - hüpertensioon - kardiovaskulaarsüsteem - ravi oluline hüpertensioon täiskasvanud:lisada therapyonduarp on näidustatud täiskasvanutel, kelle vererõhk ei ole adekvaatselt kontrollitav kohta amlodipine. asendamine therapyadult saavate patsientide telmisartan ja amlodipine alates eraldi tablette võib selle asemel saada tabletid onduarp sisaldavad sama komponendi doosid.

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

viatris healthcare limited - lipaas+amülaas+proteaas - gastroresistentne kõvakapsel - 35000ühik+25200ühik+1400ühik 50tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

viatris healthcare limited - lipaas+amülaas+proteaas - gastroresistentne kõvakapsel - 20000ühik+16000ühik+1200ühik 50tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

zentiva k.s. - rosuvastatiin+esetimiib - õhukese polümeerikattega tablett - 40mg+10mg 30tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

zentiva k.s. - rosuvastatiin+esetimiib - õhukese polümeerikattega tablett - 20mg+10mg 84tk; 20mg+10mg 30tk; 20mg+10mg 28tk; 20mg+10mg 90tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

zentiva k.s. - rosuvastatiin+esetimiib - õhukese polümeerikattega tablett - 10mg+10mg 84tk; 10mg+10mg 30tk; 10mg+10mg 90tk; 10mg+10mg 28tk

欧盟 - 爱沙尼亚文 - EMA (European Medicines Agency)

pfizer limited - pneumococcal oligosaccharide serotype 18c, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 23f, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14 - pneumococcal infections; immunization - vaktsiinid - haiguste põhjustatud streptococcus pneumoniaeserotüüpide 4, 6b, 9v, 14, 18 c, 19f ja 23f (sealhulgas sepsis, meningiit, pneumoonia, baktereemia ja äge keskkõrvapõletik) imikutel ja lastel kaks kuud kuni viieaastase. kasutada prevenar tuleks kindlaks määrata, lähtudes ametlikest soovitustest, võttes arvesse mõju invasiivse haiguse erinevates vanuserühmades samuti muutlikkust ja serotüübi epidemioloogiat erinevates geograafilistes piirkondades.